PRESS RELEASE

Wednesday January 19, 2:19 pm Eastern Time

Company Press Release

SOURCE: BioMedicines, Inc.

BioMedicines, Inc. Names Peter Langecker Chief Medical Officer

ALAMEDA, Calif., Jan. 19 /PRNewswire/ -- BioMedicines, Inc. today announced that it has named Peter J. Langecker, M.D., Ph.D., as Chief Medical Officer and Vice President Clinical Affairs.

Dr. Langecker is a native of Germany and received his medical education at Ludwig-Maximilians University in Munich. He trained in hematology and oncology and gained extensive experience in developing drugs and biological products in both Europe and the United States. Dr. Langecker was formerly based in Switzerland where he developed oncologic products for Novartis. He came to the U.S. as Director of Oncology Clinical Research for Schering- Plough. More recently he served as Vice President of Clinical Affairs for Sugen, Inc. through its merger with Pharmacia & Upjohn. Dr. Langecker also serves as a Director for Xcyte Therapies of Seattle.

"We are very pleased to welcome Dr. Langecker to BioMedicines,'' said Dr. Mark Moran, chief executive officer of BioMedicines. "Because of the company's relationships with European pharmaceutical companies, especially those in Germany and Switzerland, Dr. Langecker's scientific and business knowledge are very useful. Peter is a leader who has successfully built development teams more than once.''

Dr. Langecker said, "I am very pleased to join BioMedicines and look forward to guiding the company's programs as we enter Phase 3 testing this year.''

BioMedicines, Inc., a privately held pharmaceutical company, is developing first line therapies for the treatment of cancer and infectious diseases. The company specializes in redirecting the development of drugs to new and more valuable indications. The company has current development and/or commercialization agreements with Boehringer Ingelheim, Schering AG, and G.D. Searle & Co. BioMedicines is headquartered in Alameda, California. More information about the company is available at www.biomedicinesinc.com.

| Back |